The patent filing of our ideas with confirming experimental data is a first milestone and signals an inflection point for Pantherna said Dr. Jörg Kaufmann, Chief Scientific Officer. “Now we can openly communicate Pantherna’s R&D strategy to develop novel mRNA constructs for optimized cell-type specific protein expression. Together with our extensive expertise and experience in the field of delivering nucleic acids to the vasculature Pantherna is now in a position to start its focused development campaign to test novel therapeutics modalities against several diseases with unmet medical need.”